RECRUITING

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.

Official Title

An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT)

Quick Facts

Study Start:2024-12-27
Study Completion:2027-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06633224

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the past year except surgery.
  2. * Participants receiving \>= 15 fractions.
  3. * Participants is male or female and is \>18 years of age on the day of signing the informed consent.
  4. * Ability to understand a written informed consent document.
  5. * Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.
  6. * Willing to have medical records reviewed for clinical information.
  7. * Able to read, write and understand English or Spanish.
  1. * Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).

Contacts and Locations

Study Contact

Jamese Johnson
CONTACT
(415) 530-9805
Jamese.Johnson@ucsf.edu

Principal Investigator

Sue Yom, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Sue Yom, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-27
Study Completion Date2027-09-01

Study Record Updates

Study Start Date2024-12-27
Study Completion Date2027-09-01

Terms related to this study

Keywords Provided by Researchers

  • Basic Science Research

Additional Relevant MeSH Terms

  • Cancer
  • Thoracic Cancer
  • Gynecologic Cancer
  • Head and Neck Cancer
  • Gastrointestinal Cancer